MyoKardia Readies First-Ever Hypertrophic Cardiomyopathy Drug For US Filing

The Phase III EXPLORER-HCM trial evaluating mavacamten in obstructive hypertrophic cardiomyopathy (oHCM) succeeded on all primary and secondary endpoints.

heart surround with pharmaceutical medicine pills and tablets, a flask and a pill box on blue background, heart health and treatment. top view. health concept
MyoKardia's once-daily pill bested placebo on all efficacy measures • Source: Shutterstock

MyoKardia Inc. plans to file mavacamten with the US Food and Drug Administration in the first quarter of 2021 based on results from the Phase III EXPLORER-HCM clinical trial in obstructive hypertrophic cardiomyopathy (oHCM). The company reported on 11 May that patients treated with the oral drug were less likely to experience shortness of breath than those who received placebo in the pivotal trial, and half of the patients treated with mavacamten were deemed asymptomatic by the end of the study.

The EXPLORER-HCM results show that the allosteric modulator of cardiac myosin improved patients’ heart function and symptoms while proving at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza